Moderna (MRNA) Deferred Taxes (2021 - 2023)

Moderna (MRNA) has 3 years of Deferred Taxes data on file, last reported at -$106.0 million in Q4 2023.

• On a quarterly basis, Deferred Taxes fell 0.95% year-over-year to -$106.0 million in Q4 2023; TTM through Sep 2024 was -$106.0 million, a 112.79% decrease from a year earlier, with the FY2023 full-year figure at $828.0 million, up 243.25% from the prior year.
• Deferred Taxes for Q4 2023 stood at -$106.0 million, down from $1.5 billion in the prior quarter.
• Over the last five years, Deferred Taxes for MRNA reached as high as $1.5 billion in Q3 2023 and fell as low as -$310.0 million in Q1 2023.
• Historically, Deferred Taxes has averaged -$3.8 million across 3 years, with a median of -$105.5 million in 2022.
• Across the five-year window, Deferred Taxes sank 945.45% in 2022 and jumped 1609.28% in 2023, its largest moves.
• Year by year, Deferred Taxes stood at -$207.0 million in 2021, then jumped by 49.28% to -$105.0 million in 2022, then dropped by 0.95% to -$106.0 million in 2023.
• Per Business Quant data, the three most recent Deferred Taxes figures were -$106.0 million in Q4 2023, $1.5 billion in Q3 2023, and -$220.0 million in Q2 2023.